TEPEZZA Supply Update: In January 2021, the Company submitted a prior approval supplement to the U.S. The transaction is expected to close by the end of the first quarter of 2021. Per the agreement, the Company will acquire all of Viela’s common stock for $53.00 per share in cash, which represents a fully diluted equity value of approximately $2.67 billion, net of Viela’s cash and cash equivalents. The acquisition represents a significant step forward in advancing the Company’s strategy to expand its pipeline to accelerate long-term sustainable growth by adding four pipeline candidates currently in nine development programs. 31, 2021, the Company entered into a definitive agreement to acquire Viela, a biotechnology company with a deep, mid-stage biologics pipeline for autoimmune and severe inflammatory diseases, an experienced R&D team and UPLIZNA, a recently approved biologic medicine for a rare disease. Pending Acquisition of Viela Bio, Inc.: On Jan.(in millions except for per share amounts and percentages)įourth-Quarter and Recent Company Highlights This significant progress allows us to build on the value we provide to patients and our shareholders.” Financial Highlights Our recently announced agreement to acquire Viela further strengthens this position by adding a deep mid-stage biologics pipeline and an on-market rare disease biologic, UPLIZNA. “The launch of TEPEZZA, one of the most successful rare disease medicine launches ever, strengthened our position as one of the fastest growing biotech companies. “Our outperformance in 2020 capped off a breakthrough year for Horizon,” said Tim Walbert, chairman, president and chief executive officer, Horizon. 24, 2021- Horizon Therapeutics plc (Nasdaq: HZNP) today announced record fourth-quarter and full-year 2020 financial results and provided full-year 2021 net sales and adjusted EBITDA guidance. FDA to Support a Return of TEPEZZA Supply to the Market. Submitted Prior Approval Supplement in January to the U.S. Announced Viela Acquisition to Significantly Expand Development Pipeline with Four Candidates Currently in Nine Development Programs and to Grow Rare Disease Medicines Portfolio with UPLIZNA® (inebilizumab-cdon), a Recently Approved Biologic Medicine for a Rare Autoimmune Disease. Full-Year 2021 Net Sales Guidance of $2.70 Billion to $2.80 Billion, Representing 25 Percent Growth at the Midpoint Full-Year 2021 Adjusted EBITDA Guidance of $1.14 Billion to $1.18 Billion, Representing 16 Percent Growth at the Midpoint. Record KRYSTEXXA ® (pegloticase injection) Fourth-Quarter 2020 Net Sales of $128.9 Million Record Full-Year 2020 Net Sales of $405.9 Million, Representing Net Sales Growth of 19 Percent. TEPEZZA ® (teprotumumab-trbw) Fourth-Quarter 2020 Net Sales of $343.7 Million Full-Year 2020 Net Sales of $820.0 Million, Significantly Exceeding Launch-Year Expectations Driving One of the Best Rare Disease Medicine Launches in History. Record Full-Year 2020 Net Sales of $2.20 Billion Driven by 110 Percent Growth in the Orphan Segment Full-Year 2020 GAAP Net Income of $389.8 Million Adjusted EBITDA of $998.7 Million. Record Fourth-Quarter 2020 Net Sales of $745.3 Million Increased 105 Percent Fourth-Quarter 2020 GAAP Net Income of $190.6 Million Adjusted EBITDA of $371.0 Million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |